Drug Insight: rituximab in renal disease and transplantation (original) (raw)

• Anolik JH et al. (2003) The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 48: 455–459
  Article CAS Google Scholar
• Teeling JL et al. (2004) Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104: 1793–1800
  Article CAS Google Scholar
• McLaughlin P et al. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16: 2825–2833
  Article CAS Google Scholar
• Mohrbacher A (2005) B cell non-Hodgkin's lymphoma: rituximab safety experience. Arthritis Res Ther 7 (Suppl 3): S19–S25
  Article Google Scholar
• Edwards JC et al. (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350: 2572–2581
  Article CAS Google Scholar
• Vieira CA et al. (2004) Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation 77: 542–548
  Article CAS Google Scholar
• Looney RJ et al. (2004) B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 50: 2580–2589
  Article CAS Google Scholar
• Cohen CD et al. (2005) CD20-positive infiltrates in human membranous glomerulonephritis. J Nephrol 18: 328–333
  PubMed Google Scholar
• Remuzzi G et al. (2002) Rituximab for idiopathic membranous nephropathy. Lancet 360: 923–924
  Article CAS Google Scholar
• Ruggenenti P et al. (2003) Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J Am Soc Nephrol 14: 1851–1857
  Article CAS Google Scholar
• Rossi P et al. (2005) Anti-CD20 monoclonal antibody for the treatment of refractory autoimmune haemolytic anaemia associated with idiopathic membranous nephropathy. Rheumatology (Oxford) 44: 403–405
  Article CAS Google Scholar
• Benz K et al. (2004) Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol 19: 794–797
  Article Google Scholar
• Lamprecht P et al. (2003) Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis. Ann Rheum Dis 62: 1230–1233
  Article CAS Google Scholar
• Roccatello D et al. (2004) Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 19: 3054–3061
  Article CAS Google Scholar
• Zaja F et al. (2003) Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 101: 3827–3834
  Article CAS Google Scholar
• Ghijsels E et al. (2004) Anti-CD20 monoclonal antibody (rituximab) treatment for hepatitis C-negative therapy-resistant essential mixed cryoglobulinemia with renal and cardiac failure. Am J Kidney Dis 43: e34–e38
  Article Google Scholar
• Ghobrial IM et al. (2004) Initial increase in the cryoglobulin level after rituximab therapy for type II cryoglobulinemia secondary to Waldenstrom macroglobulinemia does not indicate failure of response. Am J Hematol 77: 329–330
  Article Google Scholar
• Sfikakis PP et al. (2005) Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 52: 501–513
  Article CAS Google Scholar
• Leandro MJ et al. (2002) An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 46: 2673–2677
  Article Google Scholar
• van Vollenhoven RF et al. (2004) Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone. Scand J Rheumatol 33: 423–427
  Article CAS Google Scholar
• Smith KGC et al. (2004) A prospective trial of B-cell depletion with Rituximab in refractory SLE [abstract #113]. JASN 15
• Gottenberg J et al. (2004) Tolerance and short-term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 64: 913–920
  Article Google Scholar
• Marks SD et al. (2005) B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum 52: 3168–3174
  Article CAS Google Scholar
• Edelbauer M et al. (2005) Rituximab in childhood systemic lupus erythematosus refractory to conventional immunosuppression: case report. Pediatr Nephrol 20: 811–813
  Article Google Scholar
• Specks U et al. (2001) Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 44: 2836–2840
  Article CAS Google Scholar
• Keogh KA et al. (2005) Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52: 262–268
  Article Google Scholar
• Smith KGC et al. (2004) Effective treatment of refractory vasculitis by B cell depletion with rituximab [abstract #170]. Kidney Blood Press Res 28
• Kallenbach M et al. (2005) Rituximab induced remission in a patient with Wegener's granulomatosis. Nephron Clin Pract 99: c92–c96
  Article CAS Google Scholar
• Ferraro AJ et al. (2005) Effective therapeutic use of rituximab in refractory Wegener's granulomatosis. Nephrol Dial Transplant 20: 622–625
  Article Google Scholar
• Eriksson P (2005) Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 257: 540–548
  Article CAS Google Scholar
• Keogh KA et al. (2006) Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 173: 180–187
  Article CAS Google Scholar
• Aries PM et al. (2005) Lack of efficacy of Rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis [doi: 10.1136/ard.2005.044420]
• Omdal R et al. (2005) Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: favourable but temporary response. Scand J Rheumatol 34: 229–232
  Article CAS Google Scholar
• Mandreoli M et al. (2004) Successful resumption of epoetin alfa after rituximab treatment in a patient with pure red cell aplasia. Am J Kidney Dis 44: 757–761
  Article Google Scholar
• Yassa SK et al. (2005) Anti-CD20 monoclonal antibody (Rituximab) for life-threatening hemolytic-uremic syndrome. Clin Transplant 19: 423–426
  Article CAS Google Scholar
• Chemnitz J et al. (2002) Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab. Am J Hematol 71: 105–108
  Article CAS Google Scholar
• Stein GY et al. (2004) Treatment of resistant thrombotic thrombocytopenic purpura with rituximab and cyclophosphamide. Int J Hematol 80: 94–96
  Article Google Scholar
• Yomtovian R et al. (2004) Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature. Br J Haematol 124: 787–795
  Article Google Scholar
• Reddy PS et al. (2005) Rituximab in the treatment of relapsed thrombotic thrombocytopenic purpura. Ann Hematol 84: 232–235
  Article CAS Google Scholar
• Zheng X et al. (2003) Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab. Ann Intern Med 138: 105–108
  Article CAS Google Scholar
• Fakhouri F et al. (2005) Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood 106: 1932–1937
  Article CAS Google Scholar
• Ganne V et al. (2003) Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder. Clin Transplant 17: 417–422
  Article Google Scholar
• Al-Akash SI et al. (2005) Rapid response to rituximab in a pediatric liver transplant recipient with post-transplant lymphoproliferative disease and maintenance with sirolimus monotherapy. Pediatr Transplant 9: 249–253
  Article Google Scholar
• Book BK et al. (2005) New crossmatch technique eliminates interference by humanized and chimeric monoclonal antibodies. Transplant Proc 37: 640–642
  Article CAS Google Scholar
• Sarwal M et al. (2003) Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 349: 125–138
  Article CAS Google Scholar
• Alausa M et al. (2005) Refractory acute kidney transplant rejection with CD20 graft infiltrates and successful therapy with rituximab. Clin Transplant 19: 137–140
  Article Google Scholar
• Becker YT et al. (2004) Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 4: 996–1001
  Article CAS Google Scholar
• Samaniego M et al. (2002) Early allograft outcomes in patients with antibody mediated rejection treated with rituximab: a single center experience [abstract #259]. Am J Transplant 2 (Suppl 3)
• Tyden G et al. (2005) ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transplant 5: 145–148
  Article Google Scholar
• Sonnenday CJ et al. (2004) Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 4: 1315–1322
  Article CAS Google Scholar
• Sawada T et al. (2002) Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis. Transplantation 74: 1207–1210
  Article CAS Google Scholar
• Sawada T et al. (2004) Preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy and DFPP-enabled non-responders to undergo ABO-incompatible kidney transplantation. Clin Transplant 18: 254–260
  Article Google Scholar
• Gloor JM et al. (2005) A comparison of splenectomy versus intensive posttransplant antidonor blood group antibody monitoring without splenectomy in ABO-incompatible kidney transplantation. Transplantation 80: 1572–1577
  Article Google Scholar
• Sidner RA et al. (2004) In vivo human B-cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody. Hum Antibodies 13: 55–62
  Article CAS Google Scholar
• Gloor JM et al. (2003) Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant 3: 1017–1023
  Article Google Scholar
• Choquet S et al. (2005) Efficacy and safety of rituximab in B-cell post-transplant lymphoproliferative disorders: results of a prospective multicentre phase II study. Blood [doi: 10.1182/blood-2005-01-0377]
• Oertel SH et al. (2005) Effect of anti-CD20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 5: 2901–2906
  Article CAS Google Scholar
• Jain AB et al. (2005) Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single center. Transplantation 80: 1692–1698
  Article CAS Google Scholar
• Gong Q et al. (2005) Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 174: 817–826
  Article CAS Google Scholar
• Pijpe J et al. (2005) Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheum 52: 2740–2750
  Article CAS Google Scholar
• Kimby E (2005) Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 31: 456–473
  Article CAS Google Scholar
• Garrett HE Jr et al. (2005) Treatment of vascular rejection with rituximab in cardiac transplantation. J Heart Lung Transplant 24: 1337–1342
  Article Google Scholar